Medical Advisory Board
VIRxSYS' policy is to establish a Medical Advisory Board (MAB) for each product that enters clinical trials as well as to retain informal advisors during preclinical stages. The MAB is comprised of key experts in the field of HIV who provide guidance in the design and execution of the Company's HIV clinical trials and guidance in positioning VRX496™. The members of the Medical Advisory Board include:
| Member | Affiliation |
|---|---|
| Brigitte Autran, MD, PhD |
Groupe Hospitalier Pitie-Salpetriere Paris, France |
| Steven Deeks, MD |
University of California at San Francisco San Francisco, California |
| Carl June, MD | University of Pennsylvania Philadelphia, Pennsylvania |
| Christine Katlama, MD | Groupe Hospitalier Pitie-Salpetriere Paris, France |
| Daniel Kuritzkes, MD |
Harvard University Cambridge, Massachusetts |
| Joep Lange, MD, PhD |
Academic Medical Centre Amsterdam, The Netherlands |
| Michael Lederman, MD | Case Western Reserve University Cleveland, OH |
| Julio Montaner, MD |
British Columbia Centre for Excellence in HIV/AIDS Vancouver, British Columbia |
| Robert Murphy, MD |
Northwestern University Evanston, Illinois |
| Richard Pollard, MD |
University of California at Davis Sacramento, California |
| John Sullivan, MD |
University of Massachusetts Medical Center Worcester, Massachusetts |
| Andrew Zolopa, MD |
Stanford University Stanford, California |
"In today’s biotech environment, a company can succeed only if it reaches outside to get the best advice possible. We are fortunate to have assembled a fabulous group of the best and brightest HIV clinicians in the world for advice in our clinical trials and product positioning."
Dr. Riku Rautsola, VIRxSYS CEO